• Scientific statements explain the rationale behind inclusion and exclusion criteria, noting that advanced age, antiplatelet therapy, or very high NIHSS do not by themselves preclude benefit in the earliest window when contraindications are managed.

https://www.ahajournals.org/doi/10.1161/str.0000000000000158

• Consensus work on rapidly improving stroke symptoms concludes that persistent potentially disabling deficits should still be treated rather than excluded as “improving”.
  https://www.ahajournals.org/doi/10.1161/strokeaha.113.000878

• AHA/ASA guidelines synthesize contraindications, BP thresholds, timing, and scenarios where individualized risk–benefit applies, updating prior exclusions and clarifying mild or rapidly improving deficits.
  https://www.heart.org/-/media/Files/Professional/Quality-Improvement/Get-With-the-Guidelines/Get-With-The-Guidelines-Stroke/2019UpdateAHAASAAISGuidelineSlideDeckrevisedADL12919.pdf

• Contemporary summaries endorse thrombolysis in eligible patients and recognize the growing, guideline-supported role of tenecteplase while warning about dosing and medication errors.
  https://www.ahajournals.org/doi/10.1161/JAHA.123.031692